@article {20224,
	title = {B-CULTURE {\textendash} 4D human-based screening},
	booktitle = {SFB 2019},
	year = {2019},
	month = {2019-04-05 00:00:00},
	address = {Seattle, USA},
	abstract = {<p>B-CULTUREoffers the BIOreACT system (figure 1) to the Pharma, Cosmetic and Medical Implants Industries as a solution for relevant preclinical product screening. Typically, drugs take 12 years to be licensed and the costs reach $1.5 billion<sup>[1]</sup>. In average, 87\% of the molecules getting to the clinical trials are false positives due to low preclinical testing accuracy<sup>[2]</sup>. Notably, improving 10\% in their prediction can save up $100 million/molecule<sup>[3]</sup>. In this regard, B-CULTURE technology enables a human-like 4D environment able to control and regulate two different but connected human-like tissues (e.g. bone-cartilage, dermis-epidermis, blood-brain sides,), granting no ethical concerns unlike animal models and realistic screening unlike the in vitro alternatives. Our first products-to-market are the skin and osteochondral models. Overall, we provide a solution for monitored realistic screening of medical products.</p>},
	keywords = {B-CULTURE, Business Plan, drug screening, osteochondral model},
	url = {https://2019.biomaterials.org/},
	author = {Canadas, R. F. and Marques, A. P. and Oliveira, J. M. and Reis, R. L.}
}
